Cytochrome C Oxidase in Malignant Gliomas

恶性胶质瘤中的细胞色素 C 氧化酶

• 批准号: 8828116
• 负责人: Corinne E. Griguer
• 金额: $ 30.4万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-05-01 至 2016-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8828116
• 关键词: Accounting; Affect; Affinity; Apoptosis; Apoptotic; Biological Markers; Biopsy; Brain Neoplasms; Cancer Etiology; Cell Cycle; Cell Death; Cells; Chromosomes; Complex; Coupled; Cytochromes; DNA; DNA Repair Enzymes; Data; Development; Drug resistance; Electron Transport; Enzymes; Exhibits; Generations; Genes; Genetic; Glioblastoma; Glioma; Goals; Homeostasis; Human; Hypoxia Pathway; Integral Membrane Protein; Intracranial Neoplasms; Kinetics; Lipids; MGMT gene; Malignant Glioma; Mediating; Metabolism; Methylation; Mitochondria; Mitochondrial Proteins; Modality; Molecular; Nuclear; Outcome; Oxidases; Oxidation-Reduction; Oxidative Phosphorylation; Oxidative Regulation; Oxidative Stress; Oxygen; Palliative Care; Pathway interactions; Patients; Pharmacotherapy; Production; Prognostic Marker; Progression-Free Survivals; Property; Protein Isoforms; Proteins; Publishing; Radiation therapy; Reactive Oxygen Species; Recurrence; Recurrent tumor; Regimen; Regulation; Research; Resistance; Resistance development; Role; Specimen; Stress; Structure; Survival Rate; Testing; Therapeutic; Tissues; base; cancer cell; cancer therapy; chemotherapy; clinically significant; cytochrome c; cytochrome c oxidase; experience; glucose uptake; inhibitor/antagonist; knowledge base; mouse model; mutant; novel; novel therapeutics; outcome forecast; overexpression; oxidation; palliative; preconditioning; prognostic tool; protein complex; respiratory; response; standard of care; temozolomide; therapeutic target; tumor

DESCRIPTION (provided by applicant): Glioblastoma multiforme (GBM) is the most common primary intracranial neoplasm and its almost uniform lethality. Temozolomide (TMZ) is the standard of care for the treatment of GBM patients showing small but significant increases in median survival of 4 weeks. However, acquisition of TMZ-chemoresistance is one of the major obstacles to efficient therapy for GBM patients. Despite aggressive treatment approaches, recurrence occurs in 90% of GBM patients. One cause of this poor outcome is development of a drug resistance. The mechanism underlying drug resistance is still not well understood thus challenging the development of more effective strategies and/or novel therapeutics to overcome this resistance. Mitochondria (mt) are at the cross road of energy production and apoptotic pathways. Their role in cancer etiology is significant; however, information regarding mt function and chemoresistance remains poorly defined. The enzyme cytochrome c oxidase (CcO) (EC 1.9.3.1) is a large mt transmembrane protein complex. It is the last enzyme in the respiratory electron transport chain (ETC) that transfers electrons from cytochrome c (Cyt c) to molecular oxygen (O2). Cyt c and O2 are the main substrates of CcO and both are directly involved in the intrinsic mt apoptotic pathway and hypoxia. While most of the studies to date have focus on CcO involvement in mt oxidative phosphorylation, any casual relation between CcO activity, CcO-nuclear-encoded subunits and the development of resistance to apoptosis in GBM is unclear and is the subject of this proposal. Recently, we demonstrated that acquisition of TMZ-resistance correlates with a significant increase of CcO activity in culture glioma cells as well a paired primary-recurrent GBM patient biopsies. The discovery of similar alterations in CcO activity between primary and recurrent human GBM specimens in patients subjected to TMZ-radiotherapy emphasizes the clinical significance of the findings and the primary role of TMZ in mediating these effects. Moreover, pharmacological or genetic inhibition of CcO in TMZ-resistant cells restores TMZ-induced apoptosis. The goal of this proposal is to test the hypothesis that CcO subunit 4 isoform 1 (COX4-1) drives chemoresistance in GBM through changes in 1) CcO assembly/ function and 2) cellular redox homeostasis by achieving three specific aims: We will determine whether: (1) Determine the effects of COX4-1 and 2 isoforms on the assembly/ function of CcO and on resistance to TMZ, (2) Determine the effects of COX4-1 and 2 isoforms on cellular redox status and on resistance to TMZ and 3) Determine the activity of CcO and expression of COX4-1 and 2 isoforms in brain tumor patient biopsies. Upon completion of this research, we expect to have developed a substantial base of knowledge on the role of CcO in the apoptotic response to TMZ. Our long term goal is to apply this information for the development of CcO-based therapies as well as for the development of prognostic markers for chemoresistance and GBM recurrence.

描述（由申请方提供）：多形性胶质母细胞瘤（GBM）是最常见的原发性颅内肿瘤，其致死率几乎一致。替莫唑胺（TMZ）是治疗GBM患者的标准治疗，显示4周的中位生存期有小幅但显著的增加。然而，TMZ耐药性的获得是GBM患者有效治疗的主要障碍之一。尽管有积极的治疗方法，但90%的GBM患者会复发。这种不良结果的一个原因是耐药性的发展。耐药性的机制仍然没有得到很好的理解，因此挑战了更有效的策略和/或新的治疗方法来克服这种耐药性的发展。线粒体（mt）处于能量产生和凋亡途径的交叉路口。它们在癌症病因学中的作用是重要的;然而，关于mt功能和化疗耐药性的信息仍然不清楚。酶细胞色素c氧化酶（CcO）（EC 1.9.3.1）是一种大的跨膜蛋白复合物。它是呼吸电子传递链（ETC）中的最后一个酶，将电子从细胞色素c（Cyt c）转移到分子氧（O2）。Cyt c和O2是CcO的主要底物，两者都直接参与内源性mt凋亡途径和缺氧。虽然大多数的研究集中在线粒体氧化磷酸化的CcO参与，CcO活性，CcO核编码的亚基和GBM细胞凋亡抗性的发展之间的任何因果关系是不清楚的，是这个建议的主题。最近，我们证明了TMZ耐药性的获得与培养胶质瘤细胞以及成对的原发性复发性GBM患者活检中CcO活性的显著增加相关。在接受TMZ放疗的患者中，原发性和复发性人GBM标本之间CcO活性的相似改变的发现强调了该发现的临床意义和TMZ在介导这些效应中的主要作用。此外，TMZ抗性细胞中CcO的药理学或遗传抑制恢复TMZ诱导的细胞凋亡。本提案的目标是通过实现三个具体目标来检验CcO亚基4同种型1（COX 4 -1）通过1）CcO组装/功能和2）细胞氧化还原稳态的变化驱动GBM中的化学抗性的假设：我们将确定是否：（1）确定COX 4 -1和COX 4 - 2同种型对CcO的组装/功能和对TMZ的抗性的影响，（2）测定COX 4 -1和2同种型对细胞氧化还原状态和对TMZ的抗性的影响，和3）测定脑肿瘤患者活检组织中CcO的活性和COX 4 -1和2同种型的表达。在完成这项研究后，我们希望已经开发了一个坚实的知识基础上的作用，CcO的凋亡反应TMZ。我们的长期目标是将这些信息应用于开发基于CcO的疗法以及开发化疗耐药性和GBM复发的预后标志物。